X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Dr. Reddys Boasts Strong Russia Sales While Big Pharma Pulls

Content Team by Content Team
23rd May 2022
in Manufacturing, Middle East and South Asia, News
Dr. Reddy's Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India

While many western biopharma businesses have shied away from Russia since its invasion of Ukraine, some of those in India have stepped in to fill the hole by providing the Kremlin with medical supplies. Dr. Reddy Laboratories has been one of the Indian companies spearheading the move into Russia while simultaneously attempting to overcome logistical hurdles in delivering medications to Ukraine. Dr. Reddy announced plans to sell new medications in Russia during its quarterly profit release recently. The company, which ranks fourth among India drugmakers in terms of market capitalization, is doing exceptionally well in Russia. Its sales in Russia climbed by 70% year over year in the prior quarter. GV Prasad, Dr.  Reddy co-chairman and managing director, confirmed that their Russian operations will continue as usual. During the early stages of this ongoing crisis, their customers did some inventory stockpiling. They expect that to return to normal in the next quarter.

While several European and American pharmaceutical companies have increased humanitarian aid to Ukraine and shut down their activities in Russia, companies like Dr. Reddy have continued to supply the country with medications.

Several Indian companies have continued doing business as usual in Russia. India is in a precarious situation. To defend itself from China, the country has enlisted the help of both Russia and Europe.

The government has been silent on the Russian incursion and has refused to denounce it. Painkillers and other medications are sold in Russia by Dr. Reddy’s. They are also India’s principal supplier of Russia’s Sputnik COVID-19 vaccine. Sales to Russia amounted to more than 8% of the company’s revenue in the preceding fiscal year, which ended in March 2021, totaling $2.47 billion.

Despite delivery issues, Dr. Reddy’s said it is attempting to continue supplying pharmaceuticals to Ukraine. There has been no stoppage of funds from Russia, according to the company. Dr. Reddy’s CEO of branded markets, MV Ramana remarked that they have been in the country for three decades now and are continuing to operate as usual. Their employees’ safety has been prioritised.

Previous Post

Novel Molecular Target For Treatment of Cancer Discovered

Next Post

Scientists Uncover Sea Corals That Can Help Fight Cancer

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Regulatory Trends in Pharma
Insights

Regulatory Trends in Pharma Manufacturing to Watch in 2025

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Next Post
Scientists Uncover Sea Corals That Can Help Fight Cancer

Scientists Uncover Sea Corals That Can Help Fight Cancer

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In